AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a ...
JS and TV are supported by a senior clinical researcher fellowship from the Research Foundation Flanders (FWO). Competing ...
Notably, the eczema and asthma treatment from Sanofi and Regeneron nearly doubled the national TV ad spend of Vicks, ...
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
AbbVie, meanwhile, tumbled 12.6% after saying trials investigating its treatment for some adults with schizophrenia failed to ...
Medpage Today on MSN15d
ACG Roundup: Young-Onset Barrett's Esophagus on the RiseResearch presented at the annual American College of Gastroenterology (ACG) meeting in Philadelphia included studies on the ...
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback